Horizon Therapeutics Public Limited Company

89.34+0.9200+1.04%Vol 1.13M1Y Perf -3.79%
May 19th, 2022 16:00 DELAYED
BID82.95 ASK99.16
Open88.42 Previous Close88.42
Pre-Market- After-Market89.34
 - -  - -%
Target Price
137.00 
Analyst Rating
Strong Buy 1.05
Potential %
53.35 
Finscreener Ranking
★★★★     54.69
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★     51.64
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     69.81
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
17.96 
Earnings Rating
Neutral
Market Cap20.54B 
Earnings Date
4th May 2022
Alpha0.03 Standard Deviation0.12
Beta1.11 

Today's Price Range

88.1190.33

52W Range

82.51120.54

5 Year PE Ratio Range

-76.7071.70

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-1.21%
1 Month
-22.60%
3 Months
-4.32%
6 Months
-16.65%
1 Year
-3.79%
3 Years
252.57%
5 Years
750.86%
10 Years
2 251.05%

TickerPriceChg.Chg.%
HZNP89.340.92001.04
AAPL137.35-3.4700-2.46
GOOG2 214.91-33.1100-1.47
MSFT253.14-0.9400-0.37
XOM91.140.49000.54
WFC42.00-0.1100-0.26
JNJ173.94-1.5600-0.89
FB191.29-0.9500-0.49
GE75.740.54000.72
JPM118.31-1.7800-1.48
Financial StrengthValueIndustryS&P 500US Markets
2.90
3.60
0.35
0.53
10.10
Leverage Ratio 1.90
ProfitabilityValueIndustryS&P 500US Markets
75.90
23.80
33.80
-4.20
22.80
RevenueValueIndustryS&P 500US Markets
3.77B
16.40
39.24
27.56
Earnings HistoryEstimateReportedSurprise %
Q01 20221.151.3416.52
Q04 20211.271.4111.02
Q03 20211.541.7513.64
Q02 20210.911.6278.02
Q01 20210.070.03-57.14
Q04 20201.051.2821.90
Q03 20201.001.7474.00
Q02 20200.400.437.50
Earnings Per EndEstimateRevision %Trend
6/2022 QR1.36-0.73Negative
9/2022 QR1.54-3.75Negative
12/2022 FY5.59-6.83Negative
12/2023 FY7.12-3.13Negative
Next Report Date-
Estimated EPS Next Report1.15
Estimates Count4
EPS Growth Next 5 Years %12.70
Volume Overview
Volume1.13M
Shares Outstanding229.88K
Shares Float227.94M
Trades Count20.04K
Dollar Volume100.83M
Avg. Volume1.77M
Avg. Weekly Volume1.46M
Avg. Monthly Volume2.03M
Avg. Quarterly Volume1.81M

Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) stock closed at 89.34 per share at the end of the most recent trading day (a 1.04% change compared to the prior day closing price) with a volume of 1.13M shares and market capitalization of 20.54B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 1395 people. Horizon Therapeutics Public Limited Company CEO is Timothy P. Walbert.

The one-year performance of Horizon Therapeutics Public Limited Company stock is -3.79%, while year-to-date (YTD) performance is -17.09%. HZNP stock has a five-year performance of 750.86%. Its 52-week range is between 82.51 and 120.535, which gives HZNP stock a 52-week price range ratio of 17.96%

Horizon Therapeutics Public Limited Company currently has a PE ratio of 24.80, a price-to-book (PB) ratio of 4.31, a price-to-sale (PS) ratio of 5.54, a price to cashflow ratio of 17.20, a PEG ratio of 2.32, a ROA of 10.68%, a ROC of 13.25% and a ROE of 20.39%. The company’s profit margin is 22.80%, its EBITDA margin is 33.80%, and its revenue ttm is $3.77 Billion , which makes it $16.40 revenue per share.

Of the last four earnings reports from Horizon Therapeutics Public Limited Company, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.15 for the next earnings report. Horizon Therapeutics Public Limited Company’s next earnings report date is -.

The consensus rating of Wall Street analysts for Horizon Therapeutics Public Limited Company is Strong Buy (1.05), with a target price of $137, which is +53.35% compared to the current price. The earnings rating for Horizon Therapeutics Public Limited Company stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Horizon Therapeutics Public Limited Company has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Horizon Therapeutics Public Limited Company has a Sell technical analysis rating based on Technical Indicators (ADX : 13.73, ATR14 : 4.10, CCI20 : -61.74, Chaikin Money Flow : -0.09, MACD : -4.60, Money Flow Index : 28.41, ROC : -9.83, RSI : 36.14, STOCH (14,3) : 28.20, STOCH RSI : 0.47, UO : 52.51, Williams %R : -71.80), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Horizon Therapeutics Public Limited Company in the last 12-months were: Andy Pasternak (Option Excercise at a value of $1 372 710), Andy Pasternak (Sold 64 243 shares of value $6 989 735 ), Barry J. Moze (Option Excercise at a value of $1 118 556), Barry J. Moze (Sold 110 819 shares of value $11 750 219 ), Brian K. Beeler (Option Excercise at a value of $1 458 074), Brian K. Beeler (Sold 103 041 shares of value $10 976 099 ), Elizabeth H.Z. Thompson (Option Excercise at a value of $0), Elizabeth H.Z. Thompson (Sold 15 640 shares of value $1 738 477 ), Jeffrey W. Sherman (Option Excercise at a value of $622 646), Jeffrey W. Sherman (Sold 148 356 shares of value $15 419 044 ), Michael DesJardin (Option Excercise at a value of $0), Michael DesJardin (Sold 55 214 shares of value $5 688 453 ), Michael G. Grey (Option Excercise at a value of $11 850), Michael G. Grey (Sold 5 000 shares of value $500 200 ), Miles W. Mchugh (Option Excercise at a value of $1 759 775), Miles W. Mchugh (Sold 79 484 shares of value $8 474 584 ), Paul W. Hoelscher (Option Excercise at a value of $5 133 670), Paul W. Hoelscher (Sold 355 553 shares of value $39 113 922 ), Timothy P. Walbert (Option Excercise at a value of $3 485 611), Timothy P. Walbert (Sold 575 000 shares of value $57 070 218 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
10 (90.91 %)
10 (90.91 %)
9 (90.00 %)
Moderate Buy
1 (9.09 %)
1 (9.09 %)
1 (10.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.05
Strong Buy
1.05
Strong Buy
1.05

Horizon Therapeutics Public Limited Company

Horizon Therapeutics PLC is a specialty and generic drug manufacturing company. The company is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. The company has two reportable segments: orphan and rheumatology segment and the inflammation segment. It markets medicines in the areas of orphan diseases, rheumatology and inflammation division. The majority of revenue is generated in the United States.

CEO: Timothy P. Walbert

Telephone: +353 17722100

Address: 1 Burlington Road, Dublin D04 C5Y6, , IE

Number of employees: 1 395

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

67%33%

Bearish Bullish

64%36%

Bearish Bullish

63%37%

Bearish Bullish

58%42%

News

Stocktwits